281 related articles for article (PubMed ID: 37623017)
1. Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma.
Hui G; Stefanoudakis D; Zektser Y; Isaacs DJ; Hannigan C; Pantuck AJ; Drakaki A
Curr Oncol; 2023 Aug; 30(8):7398-7411. PubMed ID: 37623017
[TBL] [Abstract][Full Text] [Related]
2. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
[TBL] [Abstract][Full Text] [Related]
3. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options.
Park I; Lee JL
Korean J Intern Med; 2020 Jul; 35(4):834-853. PubMed ID: 32668516
[TBL] [Abstract][Full Text] [Related]
5. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
7. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint.
Tripathi A; MacDougall K; Sonpavde GP
Drugs; 2022 Nov; 82(17):1649-1662. PubMed ID: 36441503
[TBL] [Abstract][Full Text] [Related]
9. Current Therapy for Metastatic Urothelial Carcinoma.
Nadal R; Clara JA; Valderrama BP; Bellmunt J
Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
11. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
[TBL] [Abstract][Full Text] [Related]
12. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.
Wong RL; Ferris LA; Do OA; Holt SK; Ramos JD; Crabb SJ; Sternberg CN; Bellmunt J; Ladoire S; De Giorgi U; Harshman LC; Vaishampayan UN; Necchi A; Srinivas S; Pal SK; Niegisch G; Dorff TB; Galsky MD; Yu EY
Oncologist; 2021 Dec; 26(12):1026-1034. PubMed ID: 34355457
[TBL] [Abstract][Full Text] [Related]
14. [New aspects of chemotherapy and indications for maintenance immunotherapy in urothelial cancers].
Maráz A; Varga L; Pósfai B; Géczi L; Küronya Z
Magy Onkol; 2021 Dec; 65(4):329-337. PubMed ID: 34874364
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in the treatment of advanced bladder cancer.
Godwin JL; Hoffman-Censits J; Plimack E
Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
17. Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.
Tassinari E; Mollica V; Nuvola G; Marchetti A; Rosellini M; Massari F
Cancer Manag Res; 2022; 14():1945-1960. PubMed ID: 35720644
[TBL] [Abstract][Full Text] [Related]
18. Updates and novel treatments in urothelial carcinoma.
Hanna KS
J Oncol Pharm Pract; 2019 Apr; 25(3):648-656. PubMed ID: 30304985
[TBL] [Abstract][Full Text] [Related]
19. Enfortumab vedotin - next game-changer in urothelial cancer.
Maas M; Stühler V; Walz S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
[No Abstract] [Full Text] [Related]
20. [ANTIBODY-DRUG CONJUGATES - A NOVEL APPROACH FOR THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA].
Sternschuss M; Sarfaty M
Harefuah; 2022 Jan; 161(1):49-54. PubMed ID: 35077061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
